Neonatal Abstinence Syndrome
Conditions
Keywords
Opiate use during pregnancy, Clonidine, Morphine, Prenatal opiate, Neonatal Abstinence Syndrome, Infant, Newborn, Diseases, Substance-Related Disorders, Chemically-Induced Disorders, Opiate Alkaloids, Mental Disorders, Narcotics, Central Nervous System Depressants, Physiological Effects of Drugs, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Molecular Mechanisms of Pharmacological Action, Antihypertensive Agents, Analgesics, Peripheral Nervous System Agents, Sympatholytics, Autonomic Agents, Neurotransmitter Agents
Brief summary
The long term goals of our research are to establish the best pharmacological treatment for NAS and determine how pharmacologic treatment of NAS affects long-term developmental outcomes. The objective of this application is to evaluate the effectiveness of clonidine as a treatment for neonates with NAS, in a randomized clinical trial. Our central hypothesis is that clonidine will effectively treat drug withdrawal manifestations in neonates.
Detailed description
In this current proposal, the research plan is based on our pilot study, which randomized infants with NAS to receive morphine or clonidine. The treatment groups were similar as to mean birth weight, gestational age, Apgar scores, and postnatal age at treatment. Infants enrolled had no other medical or surgical complications. Treatment was initiated per our NICU standard at the time, and will be continued in this protocol. Total LOS was shorter by about 1 week in the clonidine (mean of 15 days), compared to 21 days in the morphine group. Aims and Objectives: To determine whether the treatment of NAS with a non-opiate medication, clonidine, will be more effective than morphine * Compare Clonidine and morphine for the treatment of NAS. Compare the efficacy of each drug which is determined by duration of treatment in number of days, number of dose escalations needed to achieve needed treatment, and the need for second drug treatment. * Evaluate the neurobehavioral performance scores (habituation, orientation, self- regulation, motor/reflexes, and stress/ abstinence scales) using the neonatal intensive care (NICU) network neurobehavioral scale (NNNS) in both treatment groups. This exam will take place after treatment begins, and at one month post-natal age (38-44 weeks post menstrual age) or at discharge, whichever comes first. To determine whether treatment of NAS with clonidine will result in better early childhood outcomes than those treated with morphine • Compare the cognitive, motor and behavioral development of children in both treatment groups using the Bayley III Scales of Infant Development at 6 months, one and two years of age. To build population pharmacokinetic/pharmacodynamic models and determine factors that affect exposure and response to morphine and clonidine • Measure blood levels obtained at random times and correlate to Finnegan scores. The pharmacodynamics may help with understanding NAS medications and coping measures in babies.
Interventions
1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Sponsors
Study design
Masking description
The study will mask parents and child caregivers, and NICU nurses giving the drug, other personnel, residents and attending physicians, and research staff. Since initial dose is set using weight based-dosing, a physician's order can be entered in the electronic medical record to give the initial study drug with the infant's weight stated in the order. Increase in dosing will be ordered as to increase by 25% of initial dose or decrease of dose by 10% of maximum dose. During the pilot study, masking of treating personnel was maintained while the hospital pharmacist was the only person aware of which study drug the infant was receiving. The examiners for administration of the NNNS and the research nurse and research case worker will be masked to treatment received. Those seeing the infant in the clinic will also be masked to the treatment assignment. Morphine and clonidine are dispensed in identical appearance, color, smell, and volume.
Intervention model description
The study is intended to treat NAS using a randomized and double-blind study design to compare the use of opiate (morphine) or non-opiate (clonidine). Newborns meeting the study criteria for drug withdrawal and treatment will be randomized to receive one of the drugs (morphine, clonidine). Newborns requiring a second drug to help relieve the symptoms will be treated with phenobarbital for both groups. Randomization, blinding and dispensing will occur in the Investigational Drug Services Unit. Nursing personnel in the NICU will be masked to the treatment administered to each baby.
Eligibility
Inclusion criteria
* Gestational age (GA) \> or equal to 35 weeks * Known prenatal opiate exposure (by mother admitting use, mom with positive opiate screen during pregnancy, or positive neonatal urine and meconium screening) * No known prenatal cocaine exposure * No morphine or clonidine dose before enrollment * Symptomatic with Finnegan scores (FS): 3 consecutive scores greater than or equal to 8, OR 2 consecutive scores greater than or equal to 12, and/or with attending decision to treat for NAS * Less than or equal to 7 days of age * Attending physician decides to start pharmacologic treatment and agrees to infant's study participation
Exclusion criteria
* Seizures * Major congenital malformations * Blood pressure instability * Major medical condition in addition to NAS * Parents unable to understand English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Baseline (5-10 days post natal age) and one-month post-natal age (between 4-6 weeks of age), or at discharge, whichever comes first. | The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29-8.4), Handling (0-1), quality of movement (1.20-6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43-6.67), hypertonicity (0-8), hypotonicity (0-5.0), excitability (0-11), lethargy (0-11.0), and stress/abstinence (0-0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. |
| Bayley Scales of Infant and Toddler Development Third Edition | 6 months of life | Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score. |
| Ages and Stages Questionnaire Third Edition (ASQ-3) | 12 months of age | The ASQ-3 is a developmental screening tool to assess developmental progress in children. Children are scored in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal/social skills. The child's parent/guardian answers whether their child already does an activity (yes=10), sometimes does it (sometimes=5), or does not yet do it (not yet=0). The answers are then used to score each category. Each category is then broken down into whether the child falls above the cutoff (child development is on schedule), close to the cutoff (child development is slightly delayed and requires monitoring/intervention), or below the cutoff (delayed development and further assessment required). |
| Childhood Behavior Checklist (CBCL) T-Scores | Once post discharge (between 18 months up to 24 months of age) | The CBCL/1.5-5 is validated for children ages 1.5 to 5 years old. It obtains caregivers' ratings of 113 behavior items. Scores are broken down into internalizing problems (scores range 29-100, normal is below 60), externalizing problems (scores range from 28-100, normal is below 60), and total problems (range is 28-100, normal is below 60). Items are scored on the following syndrome scales: Emotionally Reactive, Anxious/Depressed, Somatic Complaints, Withdrawn, Attention Problems, Aggressive Behavior, and Sleep Problems. Items are also scored on the following DSM-oriented scales: Affective Problems, Anxiety Problems, Pervasive Developmental Problems, Attention Deficit/Hyperactivity Problems, Stress Problems, Autism Spectrum Problems, and Oppositional Defiant Problems. The CBCL consists of 113 items, scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Treatment | 60 days | Total number days of treatment |
| Childhood Behavior Checklist 1.5-5 T-Scores | Once post discharge (between 18 months up to 24 months of age) | On the CBCL 1.5-5, T-scores, with a mean of 50 and a standard deviation of 10, are used to interpret results, with scores of 65 or higher indicating a clinical range, and scores between 60 and 64 suggesting a borderline clinical range. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Clonidine Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
Clonidine: 1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs. | 60 |
| Morphine Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
Morphine: Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs. | 60 |
| Total | 120 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Physician Decision | 2 | 3 |
Baseline characteristics
| Characteristic | Clonidine | Morphine | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 60 Participants | 60 Participants | 120 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 38.7 weeks STANDARD_DEVIATION 1.2 | 38.3 weeks STANDARD_DEVIATION 1.3 | 38.4 weeks STANDARD_DEVIATION 1.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 4 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 60 Participants | 56 Participants | 116 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 6 Participants | 8 Participants | 14 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 53 Participants | 52 Participants | 105 Participants |
| Region of Enrollment United States | 60 participants | 60 participants | 120 participants |
| Sex: Female, Male Female | 23 Participants | 30 Participants | 53 Participants |
| Sex: Female, Male Male | 37 Participants | 30 Participants | 67 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 60 | 0 / 60 |
| other Total, other adverse events | 52 / 60 | 24 / 60 |
| serious Total, serious adverse events | 9 / 60 | 15 / 60 |
Outcome results
Ages and Stages Questionnaire Third Edition (ASQ-3)
The ASQ-3 is a developmental screening tool to assess developmental progress in children. Children are scored in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal/social skills. The child's parent/guardian answers whether their child already does an activity (yes=10), sometimes does it (sometimes=5), or does not yet do it (not yet=0). The answers are then used to score each category. Each category is then broken down into whether the child falls above the cutoff (child development is on schedule), close to the cutoff (child development is slightly delayed and requires monitoring/intervention), or below the cutoff (delayed development and further assessment required).
Time frame: 24 months
Population: The ASQ-3 at 24 months was used for babies who were unable to have the Bayley assessment due to COVID-19 research restrictions.~The babies who had the Bayley did not have the ASQ performed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Close to cutoffs | 1 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Below cutoffs | 2 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Close to cutoffs | 2 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Above cutoffs | 12 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Below cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Close to cutoffs | 2 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Above cutoffs | 13 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Below cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Above cutoffs | 8 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Above cutoffs | 12 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Below cutoffs | 4 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Close to cutoffs | 1 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Close to cutoffs | 4 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Below cutoffs | 1 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Above cutoffs | 8 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Above cutoffs | 8 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Close to cutoffs | 2 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Below cutoffs | 1 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Above cutoffs | 10 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Close to cutoffs | 1 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Above cutoffs | 8 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Close to cutoffs | 3 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Above cutoffs | 9 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Close to cutoffs | 2 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Above cutoffs | 10 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Close to cutoffs | 1 Participants |
Ages and Stages Questionnaire Third Edition (ASQ-3)
The ASQ-3 is a developmental screening tool to assess developmental progress in children. Children are scored in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal/social skills. The child's parent/guardian answers whether their child already does an activity (yes=10), sometimes does it (sometimes=5), or does not yet do it (not yet=0). The answers are then used to score each category. Each category is then broken down into whether the child falls above the cutoff (child development is on schedule), close to the cutoff (child development is slightly delayed and requires monitoring/intervention), or below the cutoff (delayed development and further assessment required).
Time frame: 12 months of age
Population: ASQ-3 assessments were used for babies who were unable to have Bayley assessment performed due to COVID-19 research restrictions. The babies who had the Bayley did not have the ASQ.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Above cutoffs | 6 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Below cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Close to cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Above cutoffs | 4 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Below cutoffs | 1 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Close to cutoffs | 3 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Below cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Below cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Close to cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Above cutoffs | 7 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Above cutoffs | 7 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Close to cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Close to cutoffs | 1 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Below cutoffs | 0 Participants |
| Clonidine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Above cutoffs | 6 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Above cutoffs | 7 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Close to cutoffs | 3 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Communication | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Above cutoffs | 10 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Close to cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Gross motor | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Above cutoffs | 8 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Close to cutoffs | 2 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Fine motor | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Above cutoffs | 9 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Close to cutoffs | 1 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Problem solving | Below cutoffs | 0 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Above cutoffs | 10 Participants |
| Morphine | Ages and Stages Questionnaire Third Edition (ASQ-3) | Personal/social | Close to cutoffs | 0 Participants |
Bayley Scales of Infant and Toddler Development Third Edition
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.
Time frame: 6 months of life
Population: Participants may not have had the 6 month Bayley due to the participant being lost to follow up, or because of COVID-19 research restrictions.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Cognitive | 113.0 score on a scale | Standard Deviation 12.8 |
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Language | 91.8 score on a scale | Standard Deviation 13.4 |
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Motor | 102.4 score on a scale | Standard Deviation 16.4 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Cognitive | 111.8 score on a scale | Standard Deviation 11.1 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Language | 87.7 score on a scale | Standard Deviation 13.5 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Motor | 97.4 score on a scale | Standard Deviation 12.3 |
Bayley Scales of Infant and Toddler Development Third Edition
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.
Time frame: 1 year of life
Population: Participants may not have had the 12 month Bayley due to the participant being lost to follow up, or because of COVID-19 research restrictions.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Cognitive | 98.2 score on a scale | Standard Deviation 11.5 |
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Language | 91.8 score on a scale | Standard Deviation 11.6 |
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Motor | 99.1 score on a scale | Standard Deviation 12.2 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Cognitive | 97.2 score on a scale | Standard Deviation 10.8 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Language | 92.2 score on a scale | Standard Deviation 12.2 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Motor | 96.2 score on a scale | Standard Deviation 9.3 |
Bayley Scales of Infant and Toddler Development Third Edition
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.
Time frame: 2 years of life
Population: Participants may not have had the 24 month Bayley due to the participant being lost to follow up, or because of COVID-19 research restrictions.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Cognitive | 84.3 score on a scale | Standard Deviation 6.7 |
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Language | 95.4 score on a scale | Standard Deviation 9.4 |
| Clonidine | Bayley Scales of Infant and Toddler Development Third Edition | Motor | 97.6 score on a scale | Standard Deviation 7.2 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Cognitive | 81.1 score on a scale | Standard Deviation 9.6 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Language | 86.2 score on a scale | Standard Deviation 11 |
| Morphine | Bayley Scales of Infant and Toddler Development Third Edition | Motor | 96.0 score on a scale | Standard Deviation 9.8 |
Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)
The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29-8.4), Handling (0-1), quality of movement (1.20-6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43-6.67), hypertonicity (0-8), hypotonicity (0-5.0), excitability (0-11), lethargy (0-11.0), and stress/abstinence (0-0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance.
Time frame: Baseline (5-10 days post natal age) and one-month post-natal age (between 4-6 weeks of age), or at discharge, whichever comes first.
Population: Some babies were unable to be assessed in certain domains and therefore were not included in the total analyzed for that domain.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Handling | -0.1 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Arousal | -0.1 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Regulation | 0.5 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Hypertonia | -1.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Attention | 1.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Hypotonia | 0.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Non-optimal reflexes | -1.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Excitability | -1.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Quality of movement | 0.1 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Lethargy | 0.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Asymmetry total/reflexes | 0.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Stress abstinence | 0.0 score on a scale |
| Clonidine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Habituation | 0.5 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Stress abstinence | 0.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Habituation | 0.3 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Attention | 0.6 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Handling | 0.1 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Quality of movement | 0.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Regulation | -0.2 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Non-optimal reflexes | -1.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Asymmetry total/reflexes | 0.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Arousal | 0.4 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Hypertonia | 0.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Hypotonia | 0.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Excitability | 1.0 score on a scale |
| Morphine | Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) | Lethargy | 0.0 score on a scale |
Childhood Behavior Checklist (CBCL) T-Scores
The CBCL/1.5-5 is validated for children ages 1.5 to 5 years old. It obtains caregivers' ratings of 113 behavior items. Scores are broken down into internalizing problems (scores range 29-100, normal is below 60), externalizing problems (scores range from 28-100, normal is below 60), and total problems (range is 28-100, normal is below 60). Items are scored on the following syndrome scales: Emotionally Reactive, Anxious/Depressed, Somatic Complaints, Withdrawn, Attention Problems, Aggressive Behavior, and Sleep Problems. Items are also scored on the following DSM-oriented scales: Affective Problems, Anxiety Problems, Pervasive Developmental Problems, Attention Deficit/Hyperactivity Problems, Stress Problems, Autism Spectrum Problems, and Oppositional Defiant Problems. The CBCL consists of 113 items, scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often)
Time frame: Once post discharge (between 18 months up to 24 months of age)
Population: Only children in the treated cohorts had the CBCL.~Participants who were considered lost to follow up did not have the CBCL.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Clonidine | Childhood Behavior Checklist (CBCL) T-Scores | Internalizing Problems | 52.31 score on a scale | Standard Deviation 10.4 |
| Clonidine | Childhood Behavior Checklist (CBCL) T-Scores | Externalizing Problems | 54.8 score on a scale | Standard Deviation 13.4 |
| Clonidine | Childhood Behavior Checklist (CBCL) T-Scores | Total Problems | 53.6 score on a scale | Standard Deviation 12.6 |
| Morphine | Childhood Behavior Checklist (CBCL) T-Scores | Internalizing Problems | 50.9 score on a scale | Standard Deviation 13.9 |
| Morphine | Childhood Behavior Checklist (CBCL) T-Scores | Externalizing Problems | 53.5 score on a scale | Standard Deviation 17 |
| Morphine | Childhood Behavior Checklist (CBCL) T-Scores | Total Problems | 53.5 score on a scale | Standard Deviation 13.5 |
Childhood Behavior Checklist 1.5-5 T-Scores
On the CBCL 1.5-5, T-scores, with a mean of 50 and a standard deviation of 10, are used to interpret results, with scores of 65 or higher indicating a clinical range, and scores between 60 and 64 suggesting a borderline clinical range.
Time frame: Once post discharge (between 18 months up to 24 months of age)
Population: Participants who were lost to follow up did not have the CBCL.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Clonidine | Childhood Behavior Checklist 1.5-5 T-Scores | Internalizing Problems Borderline T-Scores | 5 Participants |
| Clonidine | Childhood Behavior Checklist 1.5-5 T-Scores | Internalizing Problems Clinical Range T-Scores | 1 Participants |
| Clonidine | Childhood Behavior Checklist 1.5-5 T-Scores | Externalizing Problems Borderline T-Scores | 2 Participants |
| Clonidine | Childhood Behavior Checklist 1.5-5 T-Scores | Externalizing Problems Clinical Range T-Scores | 3 Participants |
| Clonidine | Childhood Behavior Checklist 1.5-5 T-Scores | Total Problems Borderline T-Scores | 3 Participants |
| Clonidine | Childhood Behavior Checklist 1.5-5 T-Scores | Total Problems Clinical Range T-Scores | 1 Participants |
| Morphine | Childhood Behavior Checklist 1.5-5 T-Scores | Total Problems Borderline T-Scores | 2 Participants |
| Morphine | Childhood Behavior Checklist 1.5-5 T-Scores | Internalizing Problems Borderline T-Scores | 2 Participants |
| Morphine | Childhood Behavior Checklist 1.5-5 T-Scores | Externalizing Problems Clinical Range T-Scores | 6 Participants |
| Morphine | Childhood Behavior Checklist 1.5-5 T-Scores | Internalizing Problems Clinical Range T-Scores | 8 Participants |
| Morphine | Childhood Behavior Checklist 1.5-5 T-Scores | Total Problems Clinical Range T-Scores | 8 Participants |
| Morphine | Childhood Behavior Checklist 1.5-5 T-Scores | Externalizing Problems Borderline T-Scores | 2 Participants |
Duration of Treatment
Total number days of treatment
Time frame: 60 days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Clonidine | Duration of Treatment | 17 days |
| Morphine | Duration of Treatment | 15 days |